Sgalla, Giacomo
 Distribuzione geografica
Continente #
NA - Nord America 1.838
AS - Asia 1.721
EU - Europa 1.127
SA - Sud America 420
AF - Africa 61
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.171
Nazione #
US - Stati Uniti d'America 1.773
SG - Singapore 803
CN - Cina 359
BR - Brasile 358
IT - Italia 267
VN - Vietnam 215
SE - Svezia 213
DE - Germania 132
FR - Francia 125
GB - Regno Unito 73
IE - Irlanda 67
PL - Polonia 62
ID - Indonesia 51
HK - Hong Kong 50
RU - Federazione Russa 50
JP - Giappone 46
IN - India 43
FI - Finlandia 29
KR - Corea 29
MX - Messico 27
CA - Canada 24
AR - Argentina 23
BD - Bangladesh 23
AT - Austria 22
IQ - Iraq 16
UA - Ucraina 15
ZA - Sudafrica 15
BE - Belgio 13
ES - Italia 12
MA - Marocco 12
SA - Arabia Saudita 12
TR - Turchia 12
IR - Iran 11
NL - Olanda 11
EC - Ecuador 10
PK - Pakistan 9
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
EG - Egitto 8
PY - Paraguay 8
LT - Lituania 7
UZ - Uzbekistan 7
KE - Kenya 6
TN - Tunisia 6
CH - Svizzera 5
CI - Costa d'Avorio 5
PH - Filippine 5
RO - Romania 5
CO - Colombia 4
CR - Costa Rica 4
TW - Taiwan 4
AL - Albania 3
AZ - Azerbaigian 3
DZ - Algeria 3
ET - Etiopia 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
AU - Australia 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
HN - Honduras 2
IL - Israele 2
JO - Giordania 2
LV - Lettonia 2
OM - Oman 2
PE - Perù 2
TT - Trinidad e Tobago 2
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BY - Bielorussia 1
CG - Congo 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
JM - Giamaica 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MN - Mongolia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
TZ - Tanzania 1
Totale 5.171
Città #
Singapore 446
San Jose 251
Chandler 207
Ashburn 178
Beijing 98
The Dalles 84
Rome 82
Ho Chi Minh City 73
Dublin 67
Milan 59
Lauterbourg 53
Warsaw 52
Hefei 50
New York 49
Jakarta 46
Tokyo 46
Hanoi 45
Hong Kong 45
Los Angeles 43
Frankfurt am Main 37
San Mateo 32
São Paulo 31
St Louis 30
Princeton 29
Boston 28
Fairfield 28
Moscow 26
Munich 24
Ann Arbor 22
Orem 22
Houston 21
Nuremberg 21
Santa Clara 20
Wilmington 20
North Bergen 19
Seoul 18
Council Bluffs 17
Helsinki 17
Kent 17
Dallas 16
London 16
Woodbridge 16
Chicago 15
Mexico City 15
Düsseldorf 14
Stockholm 13
Rio de Janeiro 12
Vienna 12
Shanghai 11
Atlanta 10
Brooklyn 10
Brussels 10
Chennai 10
Bremen 9
Da Nang 9
Denver 9
Jacksonville 9
Kish 9
Paris 9
Poplar 9
Portsmouth 9
Pune 9
Amsterdam 8
Augusta 8
Belo Horizonte 8
Boardman 8
Brasília 8
Casablanca 8
Curitiba 8
Phoenix 8
Catania 7
Florence 7
Guangzhou 7
Haiphong 7
Johannesburg 7
Marseille 7
Montreal 7
Turku 7
Ankara 6
Baghdad 6
Fortaleza 6
Guarulhos 6
Guayaquil 6
Hải Dương 6
Tashkent 6
Toronto 6
Abidjan 5
Asunción 5
Buenos Aires 5
Cambridge 5
Caxias do Sul 5
Dubai 5
Falkenstein 5
Goiânia 5
Lappeenranta 5
Mumbai 5
Nairobi 5
Nanjing 5
Norwalk 5
Nova Siri Scalo 5
Totale 2.952
Nome #
Residual respiratory impairment after COVID-19 pneumonia 190
Residual respiratory impairment after COVID-19 pneumonia 168
Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: Relationships with disease progression and pulmonary function trends 146
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study 134
Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study 130
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis 128
Digital lung auscultation: Will early diagnosis of fibrotic interstitial lung disease become a reality? 128
Antibody-based therapies for idiopathic pulmonary fibrosis 122
Acute Respiratory Distress Syndrome and Lung Fibrosis Complicating Surgery in a Patient with Crohn's Disease 121
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF) 119
Challenges in the diagnosis of idiopathic pulmonary fibrosis: the importance of a multidisciplinary approach 118
A randomized trial of pamrevlumab in patients with COVID-19 pneumonia 117
Case of a 33-Year-Old Woman With Hemoptysis and Migrant Nodular Cavitary Lesions 116
Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study 116
Antibody-based therapies for idiopathic pulmonary fibrosis 112
Progressive Fibrosing Interstitial Lung Disease A Proposed Integrated Algorithm for Management 111
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis 111
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't 109
Reliability of crackles in fibrotic interstitial lung disease: a prospective, longitudinal study 107
Advances with pharmacotherapy for the treatment of interstitial lung disease 107
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis 106
The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey 105
Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement 101
Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management 100
Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal? 98
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond 98
Usual Interstitial Pneumonia Pattern and Mycobacteria Lung Diseases: A Case Series 97
Promising advances in treatments for the management of idiopathic pulmonary fibrosis 96
Effectiveness of Nintedanib in Progressive Pulmonary Fibrosis Assessed by Progression Criteria: An Italian, Observational, Multicenter Study 95
Role of Stenotrophomonas maltophilia isolation in patients with non CF bronchiectasis 93
Automated system for diagnosing pulmonary fibrosis using crackle analysis in recorded lung sounds based on iterative envelope mean fractal dimension filter 90
Monitoring small airway dysfunction in connective tissue disease-related interstitial lung disease: a retrospective and prospective study 90
Restless legs syndrome: A new comorbidity in idiopathic pulmonary fibrosis 90
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis 89
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials 89
An updated safety review of the drug treatments for idiopathic pulmonary fibrosis 88
Perception of the role of Telemedicine in Interstitial Lung Diseases: ­Findings from Società Italiana di Pneumologia/ Italian Respiratory ­Society (SIP-IRS) survey 86
Phase three clinical trials in idiopathic pulmonary fibrosis 85
Reply to: Huang and Wei, Kang et al., and Ehteshami-Afshar and Raj 82
A Simple Ratio in a Complex Disease: Exploring the Neutrophil-to-Lymphocyte Ratio in Idiopathic Pulmonary Fibrosis 77
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis 77
X-ray Micro-Computed Tomography for Nondestructive Three-Dimensional (3D) X-ray Histology 72
The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials? 72
Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study 70
Do randomized clinical trials always provide certain results? 68
Better be an Agnostic than a Believer (at Least in Pulmonary Fibrosis) 60
Update in pulmonary fibrosis 2018 59
DEEP-LEARNING ANALYSIS OF HRCT IMAGES PREDICTS PULMONARY PROGRESSION AND MORTALITY IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE 56
“Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease 53
Pharmacological treatment of idiopathic pulmonary fibrosis: Time to step out of the comfort zone? 52
DEEP-LEARNING ANALYSIS OF HRCT IMAGES PREDICTS PULMONARY PROGRESSION AND MORTALITY IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE 48
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 47
COVID-related fibrosis: insights into potential drug targets 47
Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study 41
Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis 41
Impact of Chest CT Quality on the Diagnosis of Usual Interstitial Pneumonia (UIP) Pattern: A Hub and Spoke Study 23
null 19
Totale 5.270
Categoria #
all - tutte 22.785
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.785


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 0 0 0 0 0 0 11 8
2021/2022268 21 9 4 27 9 11 2 55 15 8 57 50
2022/2023558 60 69 41 87 48 54 18 42 77 34 18 10
2023/2024389 13 82 13 23 16 31 25 14 19 45 55 53
2024/20251.044 36 12 92 54 84 35 53 49 126 121 238 144
2025/20262.813 369 185 184 395 519 134 482 137 170 228 10 0
Totale 5.270